Next Article in Journal
Rounding up the Usual Suspects: Assessing Yorkie, AP-1, and Stat Coactivation in Tumorigenesis
Next Article in Special Issue
Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers
Previous Article in Journal
Antimicrobial Peptides Display Strong Synergy with Vancomycin Against Vancomycin-Resistant E. faecium, S. aureus, and Wild-Type E. coli
Previous Article in Special Issue
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
Review

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Via Mariano Semmola, 53, 80131 Napoli NA, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4579; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134579
Received: 31 May 2020 / Revised: 23 June 2020 / Accepted: 25 June 2020 / Published: 27 June 2020
(This article belongs to the Special Issue New Prognostic and Predictive Markers in Cancer Progression)
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field. View Full-Text
Keywords: TNBC; BRCA1/2; HRR; PDL1; TILs; PI3KCA; PTEN; CTCs; CSC TNBC; BRCA1/2; HRR; PDL1; TILs; PI3KCA; PTEN; CTCs; CSC
MDPI and ACS Style

Cocco, S.; Piezzo, M.; Calabrese, A.; Cianniello, D.; Caputo, R.; Di Lauro, V.; Fusco, G.; di Gioia, G.; Licenziato, M.; de Laurentiis, M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int. J. Mol. Sci. 2020, 21, 4579. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134579

AMA Style

Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Di Lauro V, Fusco G, di Gioia G, Licenziato M, de Laurentiis M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences. 2020; 21(13):4579. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134579

Chicago/Turabian Style

Cocco, Stefania, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira di Gioia, Marina Licenziato, and Michelino de Laurentiis. 2020. "Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives" International Journal of Molecular Sciences 21, no. 13: 4579. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134579

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop